Every lot published · search any lot number before you order

Retatrutide vs Semaglutide: Obesity Trial Evidence Compared

Retatrutide’s TRIUMPH-1 and semaglutide’s STEP 1 both used placebo comparators. They enrolled different study populations and assessed weight change at different times.

Retatrutide vs Semaglutide: Obesity Trial Evidence Compared. Compare study designs before outcomes. Population, Comparator, Outcome. GLP LIFE SCIENCES · RESEARCH BRIEF 32 Compare study designs before outcomes Comparisons PopulationComparatorOutcome
Compare study designs before outcomes. Illustration for this research brief.

Compare study designs before outcomes

The respective headline results can be reported side by side as a study comparison. An obesity-specific superiority claim requires a direct comparison in the same population with a common outcome definition.

InterventionTrialFollow-upMean weight reductionContext
RetatrutideTRIUMPH-180 weeks28.3% vs 2.2% placeboSponsor efficacy analysis; 12 mg arm
TirzepatideSURMOUNT-172 weeks20.9% vs 3.1% placebo15 mg arm
SemaglutideSTEP 168 weeks14.9% vs 2.4% placebo2.4 mg arm
Separate placebo-controlled trials with different protocols.

These percentages come from separate trials. Their populations, study durations, analysis methods and placebo responses differ. In SURMOUNT-5, the direct tirzepatide and semaglutide comparison yielded 20.2% and 13.7% mean reductions, respectively, at 72 weeks.

How to interpret the evidence

Keep the indication and formulation clear when reading any comparison involving semaglutide. Diabetes studies answer different questions from obesity studies.

Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.

Sources